1.Relationship of gross motor skills and perceptual motor abilities with physical activity levels in preschoolers
LI Yameng, ZHU Xiaotong, SHAO Tianzeng, YUE Fengshan, REN Yiqi, REN Yuanchun
Chinese Journal of School Health 2026;47(1):104-108
Objective:
To analyze the relationship of gross motor skills and perceptual motor abilities with physical activity levels in preschool children in a Beijing kindergarten, so as to provide a reference for promoting the development of motor competence.
Methods:
From September 2018 to March 2021, preschoolers aged 4-5 years were selected using convenience sampling method from an urban kindergarten in Beijing. The Test of Gross Motor Development-Third Version(TGMD-3) was used to assess basic preschoolers s gross motor skills ( n =152). The Pictorial Scale of Perceived Movement Skill Competence(PMSC) was used to evaluate perceptual motor skills ( n =151). Accelerometers (Actigraph GT3X) were used to record physical activity levels ( n =52). Data were analyzed using one way analysis of variance (ANOVA) and Pearson correlation coefficients.
Results:
The mean scores for gross motor skills and perceptual motor abilities were (38.76±13.48) and (35.49±6.50), respectively. The moderate to vigorous physical activity(MVPA) level was(52.60±27.44) minutes per day. No statistically significant correlations were found between gross motor skills, perceptual motor abilities MVPA among boys, girls or the overall group ( r =-0.20 to 0.25, all P >0.05). However, Boys locomotor skills, overall children s locomotor skills, and boys gross motor skills were all positively correlated with MVPA( r =0.34-0.45, all P <0.05).
Conclusion
There is a correlation between locomotor skills and physical activity levels in 4 to 5-year-old children.
2.Clinical observation of sacubitril/valsartan versus benazepril in perimenopausal hypertensive patients
Xiaoxia ZHANG ; Bolin SHAO ; Yingkun ZHOU ; Zhanhai ZHANG ; Zhiying LI
China Pharmacy 2026;37(4):476-479
OBJECTIVE To compare the antihypertensive efficacy of sacubitril/valsartan versus benazepril in patients with perimenopausal hypertension, as well as their impacts on ventricular remodeling and inflammatory fibrosis. METHODS A total of 206 perimenopausal hypertensive patients in our hospital from January 1, 2023 to December 30, 2024 were retrospectively included.These patients were enrolled and divided into benazepril group (105 cases) and sacubitril/valsartan group (101 cases). Benazepril group received Benazepril hydrochloride tablet, and sacubitril/valsartan group received Sacubitril valsartan sodium tablet. All patients were treated for 6 months. The blood pressure(systolic blood pressure and diastolic blood pressure) and blood pressure control status before and after treatment, echocardiographic indicators (left ventricular ejection fraction, left ventricular mass index, relative wall thickness, and early-diastolic peak transmitral flow velocity/early-diastolic peak velocity of the mitral annulus), inflammatory fibrosis related indicators(high-sensitivity C-reactive protein,ratio of monocytes to lymphocytes,and ratio of neutrophils to lymphocytes), as well as the occurrence of adverse reactions(hypotension,hyperkalemia,and angioedema) were observed in both groups before and after treatment. RESULTS The blood pressure control rate was significantly higher in the sacubitril/valsartan group than in benazepril group ( P <0.05). After treatment, the blood pressure, echocardiographic indicators(except for left ventricular ejection fraction) ,and inflammatory fibrosis related indicators were significantly lower than those before treatment within the same group, and the sacubitril/valsartan group were significantly lower than the benazepril group ( P <0.05). There were no statistically significant differences in the incidence of hypotension, hyperkalemia, angioedema, and overall adverse drug reactions between the two groups ( P >0.05). CONCLUSIONS Compared with benazepril, sacubitril/valsartan provides superior blood-pressure control, reverses ventricular remodeling, attenuates inflammatory fibrosis in perimenopausal hypertensive patients, while maintaining a similar safety profile.
3.Clinical research progress on cell therapy induced immune tolerance in liver transplantation
Chenliang SHAO ; Li PANG ; Chao LIU ; Leibo XU
Organ Transplantation 2026;17(2):205-211
Liver transplantation is the preferred treatment for end-stage liver disease, but recipients require long-term immunosuppressive therapy to control rejection, which may lead to complications and affect their long-term survival. Immune tolerance refers to the ability of organ transplant recipients to maintain their immune system's tolerance to the graft without relying on long-term immunosuppressants. Immune tolerance is an ideal goal pursued in the field of organ transplantation, which can reduce adverse drug reactions and improve long-term survival rates. Cell therapy has emerged as a promising strategy to induce such tolerance after liver transplantation. Therefore, this article reviews the application progress of cell therapies such as regulatory T cells, regulatory dendritic cells, mesenchymal stem cells, hematopoietic stem cells, etc. in inducing immune tolerance after liver transplantation, in order to provide reference for the clinical application of immune tolerance induction after liver transplantation.
4.Effects of medicated serum of Siwutang on autophagy of ovarian granulosa cells in polycystic ovarian syndrome
Yanshe SHAO ; Xuemei XU ; Baoqin YANG ; Huijuan LI ; Xia JI
China Pharmacy 2025;36(2):185-190
OBJECTIVE To investigate the effects of medicated serum of Siwutang on autophagy of ovarian granulosa cells (KGN cells) in polycystic ovarian syndrome (PCOS) and its underlying mechanism. METHODS Blank serum and different- concentration medicated serum of Siwutang were prepared by intragastric administration of normal saline and different doses of Siwutang [0.52, 1.04, 2.08 g/(kg·d)] in 3-month-old female SD rats. After screening the intervention concentration of Siwutang medicated serum, KGN cells were divided into control group (without any treatment), dehydroepiandrosterone (DHEA) group (treated with 50 μmol/L DHEA for 48 h), blank serum group (treated with 50 μmol/L DHEA for 48 h and with 10% blank serum for 72 h) and medium-concentration of Siwutang medicated serum group (treated with 50 μmol/L DHEA for 48 h and with 10% medium-concentration Siwutang medicated serum for 72 h). The number of autophagosomes was observed in each group, and protein expressions of pathway-related proteins [fructose-1, 6-bisphosphatase 1 (FBP1),mammalian target of rapamycin (mTOR), phosphorylated mTOR (p-mTOR)], autophagy-related proteins [p62, microtubule-associated protein 1 light chain 3 (LC3)] and mRNA expression of FBP1 were also detected. The (transfected) cells were further divided into Siwutang group (treated with 10% medium dose of Siwutang medicated serum for 72 h after 48 h intervention with 50 μmol/L DHEA), Siwutang+si-NC group [negative control small interfering RNA (siRNA) transfected cells treated with 50 μmol/L DHEA for 48 h, and then with 10% medium-concentration of Siwutang medicated serum for 72 h] and Siwutang+si-FBP1 group (FBP1 siRNA transfected cells treated with 50 μmol/L DHEA for 48 h, and then with 10% medium-concentration Siwutang medicated serum for 72 h). The effects of knocking down FBP1 on the above-mentioned effects of Siwutang were detected. RESULTS Compared with control group, DHEA group exhibited an increase in the number of autophagosomes, an elevated LC3-Ⅱ/LC3-Ⅰ and p-mTOR/mTOR, as well as increases in protein and mRNA expressions of FBP1, and decreased protein expression of p62 (P<0.05). Compared to both DHEA group and blank serum group, the medium-concentration of Siwutang medicated serum group showed a decrease in the number of autophagosomes, a decrease in LC3-Ⅱ/LC3-Ⅰ, and increases in p-mTOR/mTOR, protein expression of p62, protein and mRNA expressions of FBP1 (P<0.05). After knocking down FBP1, compared with Siwutang+si-NC group, Siwutang+si-FBP1 group showed a significant decrease in cell viability, protein expression of p62 , protein and mRNA expressions of FBP1 as well as p-mTOR/mTOR, and an increase in LC3-Ⅱ/LC3-Ⅰ (P<0.05). CONCLUSIONS Siwutang can promote the phosphorylation of mTOR protein by up- regulating the protein and mRNA expressions of FBP1 in KGN cells, thus inhibiting autophagy of KGN cells.
5.Study on patients’medicine instruction regulatory system in the European Union and the enlightenment
Sihan YUAN ; Rong JIANG ; Yujie ZHENG ; Haiqi LI ; Yixuan CHEN ; Rong SHAO
China Pharmacy 2025;36(3):269-274
OBJECTIVE To provide reference for the establishment and improvement of the regulatory system of patients’ medicine instructions in China. METHODS Through searching the official website of the European Medicines Agency (EMA) and related literature, the definition, basic nature, and content of patients’ medicine instructions in the European Union were introduced, and the characteristics of the management system of patients’ medicine instructions in the European Union were analyzed in terms of the management department, approval and change procedures, readability requirements and information accessibility requirements. At the same time, the pilot situation of patients’ medicine instructions in China, as well as problems in the paths of classification and management, readability of content, and information timeliness were analyzed to put forward suggestions. RESULTS & CONCLUSIONS European Union had a dedicated department for the management of medicine instructions; the approval and change procedures for patients’ medicine instructions were clear, the readability requirements were detailed, the readability verification program with patient participation was established, and multi-channel and timely information disclosure was adopted. It is recommended that China establish a mechanism to categorize and manage professionals’ and patients’ medicine instructions, guide multiple parties to participate in the design of patients’ medicine instructions and refine the readability requirements, and improve the mechanism for disclosure of medicine instructions to enhance the timeliness of medication information.
6.Effects of medicated serum of Siwutang on autophagy of ovarian granulosa cells in polycystic ovarian syndrome
Yanshe SHAO ; Xuemei XU ; Baoqin YANG ; Huijuan LI ; Xia JI
China Pharmacy 2025;36(2):185-190
OBJECTIVE To investigate the effects of medicated serum of Siwutang on autophagy of ovarian granulosa cells (KGN cells) in polycystic ovarian syndrome (PCOS) and its underlying mechanism. METHODS Blank serum and different- concentration medicated serum of Siwutang were prepared by intragastric administration of normal saline and different doses of Siwutang [0.52, 1.04, 2.08 g/(kg·d)] in 3-month-old female SD rats. After screening the intervention concentration of Siwutang medicated serum, KGN cells were divided into control group (without any treatment), dehydroepiandrosterone (DHEA) group (treated with 50 μmol/L DHEA for 48 h), blank serum group (treated with 50 μmol/L DHEA for 48 h and with 10% blank serum for 72 h) and medium-concentration of Siwutang medicated serum group (treated with 50 μmol/L DHEA for 48 h and with 10% medium-concentration Siwutang medicated serum for 72 h). The number of autophagosomes was observed in each group, and protein expressions of pathway-related proteins [fructose-1, 6-bisphosphatase 1 (FBP1),mammalian target of rapamycin (mTOR), phosphorylated mTOR (p-mTOR)], autophagy-related proteins [p62, microtubule-associated protein 1 light chain 3 (LC3)] and mRNA expression of FBP1 were also detected. The (transfected) cells were further divided into Siwutang group (treated with 10% medium dose of Siwutang medicated serum for 72 h after 48 h intervention with 50 μmol/L DHEA), Siwutang+si-NC group [negative control small interfering RNA (siRNA) transfected cells treated with 50 μmol/L DHEA for 48 h, and then with 10% medium-concentration of Siwutang medicated serum for 72 h] and Siwutang+si-FBP1 group (FBP1 siRNA transfected cells treated with 50 μmol/L DHEA for 48 h, and then with 10% medium-concentration Siwutang medicated serum for 72 h). The effects of knocking down FBP1 on the above-mentioned effects of Siwutang were detected. RESULTS Compared with control group, DHEA group exhibited an increase in the number of autophagosomes, an elevated LC3-Ⅱ/LC3-Ⅰ and p-mTOR/mTOR, as well as increases in protein and mRNA expressions of FBP1, and decreased protein expression of p62 (P<0.05). Compared to both DHEA group and blank serum group, the medium-concentration of Siwutang medicated serum group showed a decrease in the number of autophagosomes, a decrease in LC3-Ⅱ/LC3-Ⅰ, and increases in p-mTOR/mTOR, protein expression of p62, protein and mRNA expressions of FBP1 (P<0.05). After knocking down FBP1, compared with Siwutang+si-NC group, Siwutang+si-FBP1 group showed a significant decrease in cell viability, protein expression of p62 , protein and mRNA expressions of FBP1 as well as p-mTOR/mTOR, and an increase in LC3-Ⅱ/LC3-Ⅰ (P<0.05). CONCLUSIONS Siwutang can promote the phosphorylation of mTOR protein by up- regulating the protein and mRNA expressions of FBP1 in KGN cells, thus inhibiting autophagy of KGN cells.
7.Integrated molecular characterization of sarcomatoid hepatocellular carcinoma
Rong-Qi SUN ; Yu-Hang YE ; Ye XU ; Bo WANG ; Si-Yuan PAN ; Ning LI ; Long CHEN ; Jing-Yue PAN ; Zhi-Qiang HU ; Jia FAN ; Zheng-Jun ZHOU ; Jian ZHOU ; Cheng-Li SONG ; Shao-Lai ZHOU
Clinical and Molecular Hepatology 2025;31(2):426-444
Background:
s/Aims: Sarcomatoid hepatocellular carcinoma (HCC) is a rare histological subtype of HCC characterized by extremely poor prognosis; however, its molecular characterization has not been elucidated.
Methods:
In this study, we conducted an integrated multiomics study of whole-exome sequencing, RNA-seq, spatial transcriptome, and immunohistochemical analyses of 28 paired sarcomatoid tumor components and conventional HCC components from 10 patients with sarcomatoid HCC, in order to identify frequently altered genes, infer the tumor subclonal architectures, track the genomic evolution, and delineate the transcriptional characteristics of sarcomatoid HCCs.
Results:
Our results showed that the sarcomatoid HCCs had poor prognosis. The sarcomatoid tumor components and the conventional HCC components were derived from common ancestors, mostly accessing similar mutational processes. Clonal phylogenies demonstrated branched tumor evolution during sarcomatoid HCC development and progression. TP53 mutation commonly occurred at tumor initiation, whereas ARID2 mutation often occurred later. Transcriptome analyses revealed the epithelial–mesenchymal transition (EMT) and hypoxic phenotype in sarcomatoid tumor components, which were confirmed by immunohistochemical staining. Moreover, we identified ARID2 mutations in 70% (7/10) of patients with sarcomatoid HCC but only 1–5% of patients with non-sarcomatoid HCC. Biofunctional investigations revealed that inactivating mutation of ARID2 contributes to HCC growth and metastasis and induces EMT in a hypoxic microenvironment.
Conclusions
We offer a comprehensive description of the molecular basis for sarcomatoid HCC, and identify genomic alteration (ARID2 mutation) together with the tumor microenvironment (hypoxic microenvironment), that may contribute to the formation of the sarcomatoid tumor component through EMT, leading to sarcomatoid HCC development and progression.
8.GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in metabolic dysfunction-associated steatohepatitis livers
Yi-Tong LI ; Wei-Qing SHAO ; Zhen-Mei CHEN ; Xiao-Chen MA ; Chen-He YI ; Bao-Rui TAO ; Bo ZHANG ; Yue MA ; Guo ZHANG ; Rui ZHANG ; Yan GENG ; Jing LIN ; Jin-Hong CHEN
Clinical and Molecular Hepatology 2025;31(2):409-425
Background/Aims:
Metabolic dysfunction-associated steatohepatitis (MASH) is a significant risk factor for gallstone formation, but mechanisms underlying MASH-related gallstone formation remain unclear. Golgi membrane protein 1 (GOLM1) participates in hepatic cholesterol metabolism and is upregulated in MASH. Here, we aimed to explore the role of GOLM1 in MASH-related gallstone formation.
Methods:
The UK Biobank cohort was used for etiological analysis. GOLM1 knockout (GOLM1-/-) and wild-type (WT) mice were fed with a high-fat diet (HFD). Livers were excised for histology and immunohistochemistry analysis. Gallbladders were collected to calculate incidence of cholesterol gallstones (CGSs). Biles were collected for biliary lipid analysis. HepG2 cells were used to explore underlying mechanisms. Human liver samples were used for clinical validation.
Results:
MASH patients had a greater risk of cholelithiasis. All HFD-fed mice developed MASH, and the incidence of gallstones was 16.7% and 75.0% in GOLM1-/- and WT mice, respectively. GOLM1-/- decreased biliary cholesterol concentration and output. In vivo and in vitro assays confirmed that GOLM1 facilitated cholesterol efflux through upregulating ATP binding cassette transporter subfamily G member 5 (ABCG5). Mechanistically, GOLM1 translocated into nucleus to promote osteopontin (OPN) transcription, thus stimulating ABCG5-mediated cholesterol efflux. Moreover, GOLM1 was upregulated by interleukin-1β (IL-1β) in a dose-dependent manner. Finally, we confirmed that IL-1β, GOLM1, OPN, and ABCG5 were enhanced in livers of MASH patients with CGSs.
Conclusions
In MASH livers, upregulation of GOLM1 by IL-1β increases ABCG5-mediated cholesterol efflux in an OPN-dependent manner, promoting CGS formation. GOLM1 has the potential to be a molecular hub interconnecting MASH and CGSs.


Result Analysis
Print
Save
E-mail